Piper Sandler analyst Yasmeen Rahimi initiated coverage with a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of $21.00. The company’s shares closed yesterday at $8.04.
According to TipRanks, Rahimi is a 4-star analyst with an average return of 9.7% and a 40.96% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Crinetics Pharmaceuticals, and Savara.
In addition to Piper Sandler, Ventyx Biosciences also received a Buy from Wells Fargo’s Derek Archila in a report issued today. However, on the same day, H.C. Wainwright maintained a Hold rating on Ventyx Biosciences (NASDAQ: VTYX).
See the top stocks recommended by analysts >>
VTYX market cap is currently $587.8M and has a P/E ratio of -2.44.
Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VTYX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ventyx Biosciences (VTYX) Company Description:
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Read More on VTYX:
- Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
- Ventyx Biosciences to hold virtual investor event
- Ventyx Biosciences Secures $100M in Private Placement Deal
- Ventyx Biosciences to sell 11.17M shares at $8.95 in private placement
- Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
